MedPath

Retrospective study of Initial Acute Decline in eGFR by SGLT2-inhibitor

Not Applicable
Conditions
type 2 diabetes mellitus
Registration Number
JPRN-UMIN000039903
Lead Sponsor
Jinnouchi Hospital
Brief Summary

The mean minimum eGFR early after SGLT2i administration was 34.9 mL/min/1.73 m2, which was significantly lower than before treatment (mean, -7.7%). Seventy patients (80.5%) had IAD-eGFR, and 36 patients (41.4%) had a large IAD-eGFR (more than10%).

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
87
Inclusion Criteria

Not provided

Exclusion Criteria

Type 1 DM unstable condition cancer infection

Study & Design

Study Type
Others,meta-analysis etc
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
We retrospectively investigated how much and how frequently IAD-eGFR occurs in T2DM patients with CKD Stage-3b in the real clinical practice.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath